Prognostic value of the proliferation marker Ki‐67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial. Issue 2 (12th February 2014)

• Record Type: Journal Article
• Authors: Rademakers, Saskia E.; Hoogsteen, Ilse J.; Rijken, Paul F.; Terhaard, Chris H.; Doornaert, Patricia A.; Langendijk, Johannes A.; van den Ende, Piet; van der Kogel, Albert J.; Bussink, Johan; Kaanders, Johannes H.
• Is Part Of: Head & neck. Volume 37:Issue 2(2015:Feb.)
• Page Start: 171
• Page End: 176
• Publication Date: 2014-02-12
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23569
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="hed23569-sec-0001" sec-type="section"> <title>Background</title> <p>The prognostic and predictive value of the proliferation marker Ki‐67 was investigated in a randomized trial comparing accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON) to accelerated radiotherapy in laryngeal carcinoma.</p> </sec> <sec id="hed23569-sec-0002" sec-type="section"> <title>Methods</title> <p>Labeling index of Ki‐67 (Li Ki‐67) in immunohistochemically stained biopsies and the colocalization with carbonic anhydrase IX (CAIX) were related to tumor control and patient survival.</p> </sec> <sec id="hed23569-sec-0003" sec-type="section"> <title>Results</title> <p>On average, node‐positive patients had a higher Li Ki‐67 (median 14% vs 8%; <italic>p</italic> < .01). In patients with a high Li Ki‐67, the 5‐year regional control and metastases‐free survival were 79% versus 96% (<italic>p</italic> < .01) and 71% versus 88% (<italic>p</italic> = .05) for accelerated radiotherapy and ARCON, respectively. The 5‐year local control and disease‐specific survival were not significantly different. Patients with low Ki‐67 expression had an excellent outcome with accelerated radiotherapy alone.</p> </sec> <sec id="hed23569-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Patients with laryngeal carcinomas with high proliferative activity are at increased risk of regional and distant metastases formation. This risk can be reduced by treatment with ARCON. © 2014 Wiley Periodicals, Inc. <italic>Head Neck</italic><bold>37</bold>: 171‐176, 2015</p> </sec> </abstract>